Gastric neuroendocrine tumor with extensive ossification

A 40-year-old man underwent endoscopic ultrasound (EUS) because of suspected submucosal gastric tumor diagnosed after an episode of severe bleeding (● Fig. 1). EUS revealed a well-delineated, 18-mm hypoechoic lesion in the submucosa with a calcified area inside it (● Fig. 2, ● Video 1). Three lymph nodes near the celiac trunk showed the same characteristics of the gastric lesion: well-delineated and hypoechoic, with central calcification (● Fig. 3, ● Video 1). A fine-needle

Fig. 1 Endoscopic view in a 40-year-old man showing a gastric neoplasm with active bleeding.

Fig. 2 Ultrasonographic image of submucosal gastric tumor.

Fig. 3 The ossified lymph nodes.

aspiration (FNA) biopsy of the largest lymph node (14mm) was carried out using a 22-G needle, and histological examination revealed reactive lymphadenitis.

The patient was referred for surgery, which showed an ulcerated submucosal tumor in the anterior gastric wall with pathological lymph nodes in the coronary gastric chain. The finding of the intraoperative study was a neuroendocrine gastric tumor (● Fig. 4) with nodal neuroendocrine metastasis. All the regional lymph nodes were removed and a total gastrectomy was carried out. An intraoperative ultrasound examination was done to rule out any pancreatic or duodenal lesions.

Microscopically, the tumor consisted of uniform, small cells with round or oval nuclei and moderate atypia, lying in nests and within the bone trabeculae. The number of mitoses was 4 per 10 high power field (HPF). Extensive stromal bone formation was seen within the tumor (● Fig. 5). The tumor cells stained positive for cytokeratin, chromogranin A (● Fig. 6), synaptophysin, enolase, and

Fig. 4 Gross appearance of the gastric tumor with bone formation in the central area of tumor.

CD56, and the index of tumoral proliferation was 15%. Final histopathologic diagnosis was neuroendocrine tumor G2 (World Health Organization [WHO] classification, 2010).

Most gastric neuroendocrine tumors are multiple and associated with hypergastrinemia. Solitary tumors have a poor prognosis [1]. To our knowledge, there are only four reports of gastric carcinoid tumors with ossification [2–5]. We report a case of a type 3 (G2) neuroendocrine gastric tumor with lymph node metastases with ossification diagnosed with EUS.

Endoscopy_UCTN_Code_CCL_1AB_2AD_3AB

Competing interests: None

Video 1

Ultrasonographic exploration showing gastric mass and lymph nodes.

Fig. 5 Neuroendocrine tumor with extensive ossification.

Fig. 6 Positive immunostaining for chromogranin A.

Bibliography

DOI <http://dx.doi.org/10.1055/s-0032-1309715>
 Endoscopy 2012; 44: E271–E272
 © Georg Thieme Verlag KG
 Stuttgart · New York
 ISSN 0013-726X

Corresponding author

D. del Pozo Prieto

S. Aparato Digestivo
 H. Príncipe de Asturias
 Ctra, Alcalá-Meco 28850
 Alcalá de Henares
 Madrid
 Spain
dpozo.hupa@salud.madrid.org

**D. Del Pozo Prieto¹, M. D. Vélez²,
 L. Espinosa¹, P. González de Canales¹,
 I. Moral¹, M. Villafruela¹**

¹ S. Aparato Digestivo, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain

² S. Anatomía Patológica, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain

References

- 1 Klöppel G, Coulevard A, Perren A et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. *Neuroendocrinology* 2009; 90: 162–166
- 2 Sampsel JW, Callaway F. Gastric carcinoid with ossification. *Am J Surg* 1972; 124: 108–111
- 3 Feldman AJ, Weinberg M, Raess D et al. Gastric carcinoid tumor. Its occurrence with ossification and diffuse argyrophil-cell hyperplasia. *Arch Surg* 1981; 116: 118–121
- 4 Linz AJ, Sheridan BJ, Carney JA. Metastatic ossified gastric carcinoid with hypergastrinemia associated with gastric and thyroid autoantibodies. *J Am Osteopath Assoc* 1990; 90: 1092–1099
- 5 Yamagishi SI, Suzuki T, Ohkuro H et al. Ossifying gastric carcinoid tumor containing bone morphogenetic protein, osteopontin and osteonectin. *J Endocrinol Invest* 2004; 27: 870–873